By Robert S. Negrin, MD
Editor-in-Chief, Blood Advances
The 2019 ASH Annual Meeting marks the third anniversary of Blood Advances — the online, peer-reviewed journal published by ASH. The journal continues to grow to new heights, receiving more submissions and publishing more papers each year. We thank all of our authors, reviewers, editors, and readers for making this possible.
We are proud to highlight the important work done by our Society. The 2019 special printed edition of Blood Advances includes reports from panels convened by ASH in partnership with the U.S. Food and Drug Administration to develop consensus recommendations for clinical trial endpoints in sickle cell disease. This work will inform other efforts in ASH’s multifaceted approach to facilitate the development of new therapies and address the global burden of sickle cell disease. As with all Blood Advances publications, you may also read the papers freely online at www.BloodAdvances.org.
In addition, Blood Advances continues to publish new clinical guidelines developed through expert Committees convened through ASH, including guidelines on immune thrombocytopenia, sickle cell disease, and venous thromboembolism (VTE). Following last year’s premiere release of six guidelines related to VTE, new guidelines are being reviewed by the journal on an ongoing basis. These manuscripts represent years of work by panels of experts who reviewed available literature and thoughtfully developed key recommendations through a rigorous process, followed by comprehensive evaluation, public comment, and peer review. Watch www. BloodAdvances.org for the publication of new guidelines throughout the upcoming year.
Finally, we encourage everyone to partake in the journal’s ever-expanding content, including original articles, exceptional case reports, and a diverse set of invited material including Point-Counterpoint articles addressing controversies in hematology, Blood Advances Talks providing brief audio reviews, and Drug Advances reviews, which examine recently approved drugs from both developmental and clinical perspectives.
This has been a fantastic year at Blood Advances, thanks to our authors, readers, and reviewers. On behalf of all of our editors and staff, we hope you have enjoyed reading and listening to articles published in Blood Advances, and we welcome your suggestions and contributions.